Latest Period
Q4 2025
Security Snapshot
TENAX THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (TENX) Institutional Ownership
CUSIP: 88032L605
13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026
Institutions Reporting
48
Shares (Excl. Options)
6,948,963
Price
$12.19
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- TENX on Nasdaq
- Shares outstanding
- 25,423,286
- Price per share
- $14.96
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 6,948,963
- Total reported value
- $84,695,355
- % of total 13F portfolios
- 0%
- Share change
- +2,212,928
- Value change
- +$29,084,194
- Number of holders
- 48
- Price from insider filings
- $14.96
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TENX - TENAX THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share is tracked under CUSIP 88032L605.
- 48 institutions reported positions in Q4 2025.
- 17 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 48 to 8 between Q4 2025 and Q1 2026.
- Reported value moved from $84,695,355 to $11,899,547.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 48 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 88032L605?
CUSIP 88032L605 identifies TENX - TENAX THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 88032L605:
Significant Owners of TENAX THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (TENX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 11% | -36% | $42,503,065 | -$1,645,630 | 2,841,114 | -3.7% | T. Rowe Price Associates, Inc. | 30 Apr 2026 |
| Vestal Point Capital, LP | 9.9% | $18,525,720 | 2,470,096 | Vestal Point Capital, LP | 30 Sep 2024 | |||
| Giordano Christopher Thomas | 6.8% | $16,288,545 | 1,252,965 | Christopher Thomas Giordano | 10 Dec 2025 | |||
| Ikarian Capital, LLC | 6.7% | -55% | $13,077,042 | +$2,027,050 | 1,145,100 | +18% | Ikarian Capital, LLC | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | $11,561,410 | 768,200 | BVF PARTNERS L P/IL | 31 Dec 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $10,429,033 | +$2,106,834 | 692,959 | +25% | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 9.9% | -0.9% | $9,797,068 | +$3,499,546 | 650,968 | +56% | RTW Investments, LP | 31 Dec 2025 |
| JANUS HENDERSON GROUP PLC | 10% | +150% | $4,172,774 | +$3,057,778 | 623,733 | +274% | JANUS HENDERSON GROUP PLC | 28 Nov 2025 |
| Logos Global Management LP | 9.9% | $7,995,000 | 615,000 | Logos Global Management LP | 27 Feb 2026 | |||
| MORGAN STANLEY | 3.5% | -61% | $6,812,761 | +$2,147 | 596,564 | +0.03% | Morgan Stanley | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC | 9.1% | +30% | $8,568,085 | +$1,958,998 | 569,308 | +30% | Perceptive Advisors LLC | 31 Dec 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC | 2.1% | -69% | $7,986,979 | +$3,293,848 | 533,889 | +70% | Millennium Management LLC | 31 Mar 2026 |
| Lind Global Fund II LP | 6.6% | -24% | $6,659,324 | 442,480 | 0% | Lind Global Fund II LP | 31 Dec 2025 | |
| Invus Global Management, LLC | 2.5% | -77% | $6,390,029 | 427,141 | 0% | Raymond Debbane | 31 Mar 2026 | |
| Point72 Asset Management, L.P. | 6.8% | -8.6% | $6,372,396 | +$1,260,919 | 423,415 | +25% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| Dellora Investments LP | 6.4% | -27% | $6,036,119 | +$752,500 | 401,071 | +14% | Dellora Investments LP | 31 Dec 2025 |
| S.H.N. Financial Investments Ltd. | 5% | $1,052,814 | 179,050 | S.H.N. Financial Investments Ltd. | 31 Dec 2024 |
As of 31 Dec 2025, 48 institutional investors reported holding 6,948,963 shares of TENAX THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (TENX). This represents 27% of the company’s total 25,423,286 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of TENAX THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (TENX) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 3.8% | 967,600 | 0% | 1.5% | $11,795,044 |
| MORGAN STANLEY | 2.3% | 596,376 | +234% | 0% | $7,269,823 |
| PERCEPTIVE ADVISORS LLC | 1.7% | 439,142 | 0.1% | $5,353,141 | |
| Siren, L.L.C. | 1.7% | 427,141 | +21% | 0.16% | $5,206,849 |
| Point72 Asset Management, L.P. | 1.7% | 423,415 | 0.01% | $5,161,429 | |
| RTW INVESTMENTS, LP | 1.5% | 378,346 | 0% | 0.05% | $4,612,038 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.4% | 352,206 | 0% | 0.11% | $4,293,391 |
| BVF INC/IL | 1.3% | 339,549 | 0% | 0.14% | $4,139,102 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 302,473 | -3.6% | 0% | $3,687,146 |
| MARSHALL WACE, LLP | 1.2% | 298,153 | +68% | 0% | $3,634,484 |
| VANGUARD GROUP INC | 1% | 255,664 | +58% | 0% | $3,116,545 |
| DIADEMA PARTNERS LP | 0.96% | 243,170 | 1.8% | $2,964,242 | |
| Vivo Capital, LLC | 0.82% | 208,333 | 0% | 0.16% | $2,539,579 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.75% | 190,111 | 0.48% | $2,317,453 | |
| Integral Health Asset Management, LLC | 0.66% | 167,000 | 0% | 0.1% | $2,035,730 |
| JANUS HENDERSON GROUP PLC | 0.66% | 166,666 | 0% | 0% | $2,019,159 |
| Woodline Partners LP | 0.56% | 143,481 | +63% | 0.01% | $1,749,033 |
| FMR LLC | 0.56% | 141,100 | 0% | $1,720,009 | |
| CITADEL ADVISORS LLC | 0.51% | 129,528 | +199% | 0% | $1,578,947 |
| RENAISSANCE TECHNOLOGIES LLC | 0.49% | 125,579 | +122% | 0% | $1,530,808 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.33% | 83,333 | 0% | 0% | $1,015,829 |
| Velan Capital Investment Management LP | 0.33% | 83,333 | 0% | 0.59% | $1,015,829 |
| Persistent Asset Partners Ltd | 0.26% | 65,272 | 0.38% | $795,666 | |
| ADAR1 Capital Management, LLC | 0.25% | 63,673 | +19% | 0.06% | $776,174 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.22% | 55,699 | +62% | 0% | $678,970 |
Institutional Holders of TENAX THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (TENX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 744,358 | $11,899,547 | +$7,089,296 | $15.99 | 8 |
| 2025 Q4 | 6,948,963 | $84,695,355 | +$29,084,194 | $12.19 | 48 |
| 2025 Q3 | 4,720,738 | $35,929,590 | +$18,970,280 | $7.61 | 34 |
| 2025 Q2 | 2,231,961 | $12,926,914 | +$1,314,380 | $5.76 | 25 |
| 2025 Q1 | 2,006,422 | $13,111,231 | +$4,224,591 | $6.55 | 23 |
| 2024 Q4 | 1,362,190 | $8,426,122 | +$1,144,778 | $6.19 | 21 |
| 2024 Q3 | 1,228,920 | $4,253,022 | +$4,189,827 | $3.46 | 19 |
| 2024 Q2 | 18,829 | $57,207 | +$35,228 | $3.02 | 10 |
| 2024 Q1 | 7,235 | $30,532 | +$30,532 | $4.24 | 9 |